- PA5-17495 - Invitrogen Antibodies MARK3 antibody

Submitted references Postsynaptic density 95 (PSD-95) serine 561 phosphorylation regulates a conformational switch and bidirectional dendritic spine structural plasticity.

Wu Q, Sun M, Bernard LP, Zhang H
The Journal of biological chemistry 2017 Sep 29;292(39):16150-16160

Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression.

Dogliotti G, Kullmann L, Dhumale P, Thiele C, Panichkina O, Mendl G, Houben R, Haferkamp S, Püschel AW, Krahn MP
Nature communications 2017 Jun 26;8:15747

Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.

Henderson MX, Chung CH, Riddle DM, Zhang B, Gathagan RJ, Seeholzer SH, Trojanowski JQ, Lee VMY
The Journal of neuroscience : the official journal of the Society for Neuroscience 2017 Jun 14;37(24):5870-5884

MARK/Par1 Kinase Is Activated Downstream of NMDA Receptors through a PKA-Dependent Mechanism.

Bernard LP, Zhang H
PloS one 2015;10(5):e0124816

MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies.

Lund H, Gustafsson E, Svensson A, Nilsson M, Berg M, Sunnemark D, von Euler G
Acta neuropathologica communications 2014 Feb 17;2:22

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of Phospho-MARK Family in extracts from 293 cells transfected with either wild-type or threonine to alanine mutations at the respective phosphorylation sites of the MARK family members using Phospho-MARK Family polyclonal antibody (Product # PA5-17495). Transfected constructs contain a GST and HA tag. Transfection efficiency monitored with an HA antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of Phospho-MARK Family in extracts from Raji and BaF3 cells showing endogenous levels of phosphorylated MARK family members using Phospho-MARK Family polyclonal antibody (Product # PA5-17495).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 8 Colocalization of MARK4, phospho-MARK, and p-tau Ser 262 in GVDs. Triple-immunofluorescence images from the CA1-field of an AD case (#32) with antibodies against pMARK (FITC), MARK4 (Cy3) and p-tau Ser 262 (Cy5). (A) Arrowheads indicate neurons that stain positively for all three antibodies. (B) A typical pre-tangle neuron with perinuclear phospho-tau staining is magnified, where arrowheads indicate individual GVDs where all three markers colocalize. (C) A 3-D reconstruction of a Z-stack focused on the GVD in the bottom part of the neuron. Scale bar: 100 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 1 MARK/Par1 is regulated by synaptic activity. Hippocampal neurons were treated with either DMSO (Control) or 10 muM of picrotoxin (PTX) for one hour. After treatment, neurons were lysed and immunoblotted with the indicated antibodies. Representative blots are shown in (a) and quantifications are shown in (b), expressed as Mean +- SD. *p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 2 MARK/Par1 is activated by NMDA receptors. a. Hippocampal neurons were pretreated with CNQX and TTX for 30 minutes, then stimulated with 50 muM of NMDA for 5 min. For inhibition of NMDA receptors, APV was included in the pretreatment and during NMDA stimulation. Neurons were lysed and immunoblotted with the indicated antibodies. b. Quantifications of blots in (a). Data are Mean +- SD, *p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 3 MARK/Par1 is activated by NMDA receptors through PKA. a. Hippocampal neurons were treated with 4-AP and picrotoxin for 10 minutes. For inhibition of PKA, H-89 was included in the pretreatment and during 4-AP/PTX stimulation. Neurons were lysed and immunoblotted with the indicated antibodies. b. Quantifications of blots in (a). Data are Mean +- SD, *p

PA5-17495

Antibody data